Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Amateur Traders Corner -- Ignore unavailable to you. Want to Upgrade?

To: Frederick Langford who wrote (11305)	6/29/2001 2:56:10 PM
From: Tom Hua	Read Replies (1) \| Respond to of 19633

Fred, will do although XLNX has shown to be a difficult short, there's just too much institutional support. On another subject, here's the BW article on AVAN. Regards, Tom JULY 9, 2001 INSIDE WALL STREET Good Medicine at Avant Why would Pfizer, Merck, Bristol-Myers Squibb, or Novartis be interested in obscure Avant Immunotherapeutics (AVAN )? Answer: products in trial that target multibillion-dollar markets--cholesterol management, cardiac surgery, and vaccines for cholera and typhoid. Avant is in talks for a partner in cholesterol management, and it could be Pfizer, Merck, or Bristol-Myers. Avant has a novel vaccine in Phase 2 trials that seeks to raise the levels of high-density lipoprotein (HDL), the so-called good cholesterol. Low levels of HDL are associated with greater risk for atherosclerosis, or hardening of the arteries, which leads to heart disease and strokes. This vaccine alone targets a $4 billion market, says a money manager who owns some 3% of Avant. The company expects the vaccine to be on the market by 2006. In cardiac surgery, Avant's lead compound, TP-10, now in Phase 3 clinical trials, treats injury that occurs during surgery. Avant has received fast-track-approval status from the Food & Drug Administration for the use of TP-10 in infants undergoing surgery. Avant has a deal with Novartis to develop TP-10, due out by 2006, with a potential market of $1 billion. Mark Monane of investment firm Needham rates Avant, now trading at 5, a "strong buy," based on its products that "address large market opportunities for which current therapies are inadequate." His 12-month price target: 10. By Gene G. Marcial